EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis

Gabriel Reis Alves Carneiro iD, Isabelle Karine da Costa Nunes, Gustavo Ramalho Dos Santos Cardoso iD, Paola Façanha Dos Santos, Monica Costa Padilha iD, Fábio César Sousa Nogueira iD, Henrique Marcelo Gualberto Pereira iD

Rapid Communications in Mass Spectrometry · 15.12.2026 · 40 (23)

DOI: 10.1002/rcm.70179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, online erschienen am 15.09.2026. Verfasst von Gabriel Reis Alves Carneiro und 6 weiteren Autor:innen. Beteiligte Einrichtung: LBCD, LADETEC, Instituto de Química, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Doping in Sports, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Financiadora de Estudos e Projetos.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Retatrutide (LY3437943) is a novel long‐acting triple incretin receptor agonist that targets the glucagon‐like peptide‐1 receptor (GLP‐1R), glucose‐dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Its pronounced effects on body composition and metabolic health, combined with increasing off‐label use among physically active populations, raise concerns about potential misuse in sport. Despite growing clinical interest and anecdotal reports about use among amateur athletes, information on the detection and elimination profile of retatrutide in humans remains unexplored.

Methods

A method based on liquid chromatography–high‐resolution mass spectrometry (LC‐HRMS) dedicated to monitor retatrutide was developed and validated in human plasma and urine in accordance with World Anti‐Doping Agency (WADA) criteria. Detection was based on the [M + 3H] 3+ precursor ion by targeted selected‐ion monitoring (t‐SIM), with confirmatory analysis via parallel reaction monitoring (PRM) of structurally diagnostic fragment ions. From four retatrutide users who self‐administered 2 mg subcutaneously on Days 1 and 7, blood and urine samples were collected at predefined time points following self‐administration.

Results

The method was proved fit‐for‐purpose regarding selectivity, reliability, robustness, and stability. Limits of detection (LOD) were evaluated using both empirical ≥ 95% detection rate criteria and sigmoidal logistic regression modeling, yielding 6.14 ng/mL in plasma and 2.44 ng/mL in urine. Neither intact retatrutide nor metabolite‐derived signals were detected in urine samples throughout the entire collection period, despite systematic application of multiple extraction strategies. Plasma concentration–time profiles exhibited nonmonotonic behavior, consistent with prolonged subcutaneous absorption and depot‐like release kinetics following repeated dosing.

Conclusion

These findings suggest that plasma represents the appropriate matrix for intact retatrutide detection compared with urine. The extended plasma detection window, approximately 56 days after the first dose, supports plasma‐based testing as a suitable analytical strategy for this and related long‐acting therapeutic peptides in antidoping testing context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Doping in SportsLiquid Chromatography-Mass SpectrometryHumansMaleReproducibility of ResultsLimit of DetectionAdultChromatography, LiquidFatty AcidsPeptides

Stichwörter der Autor:innen

GLP‐1 receptor agonistLC‐HRMSLY3437943antidoping analysisincretinpeptide elimination studyplasmaretatrutide

Substanzen

retatrutideFatty AcidsPeptides

Autor:innen und Institutionen

  • LBCD, LADETEC, Instituto de Química, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
  • LABPROT, LADETEC, Instituto de Química, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.

ORCID-Profile: Gabriel Reis Alves Carneiro, Gustavo Ramalho Dos Santos Cardoso, Monica Costa Padilha, Fábio César Sousa Nogueira, Henrique Marcelo Gualberto Pereira

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Financiadora de Estudos e Projetos

Zitieren

APA

Carneiro, G. R. A., da Costa Nunes, I. K., Dos Santos Cardoso, G. R., Dos Santos, P. F., Padilha, M. C., Nogueira, F. C. S., & Pereira, H. M. G. (2026). Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis. Rapid Communications in Mass Spectrometry, 40(23). https://doi.org/10.1002/rcm.70179

Vancouver

Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, et al. Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis. Rapid Communications in Mass Spectrometry. 2026;40(23). doi:10.1002/rcm.70179

BibTeX
@article{Carneiro2026,
  author = {Carneiro, Gabriel Reis Alves and da Costa Nunes, Isabelle Karine and Dos Santos Cardoso, Gustavo Ramalho and Dos Santos, Paola Façanha and Padilha, Monica Costa and Nogueira, Fábio César Sousa and Pereira, Henrique Marcelo Gualberto},
  title = {Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC‐HRMS: Implications for Antidoping Analysis},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2026},
  volume = {40},
  number = {23},
  doi = {10.1002/rcm.70179}
}
Kostenlos starten →